Nestlé Infant Formula Recall In The UAE By Emirates Drug Establishment For Safety Review

The Emirates Drug Establishment has ordered a voluntary recall of selected Nestlé infant formula products across the UAE after traces of Bacillus cereus bacteria were detected in one raw material, with authorities stressing that this step is precautionary and focused on protecting children’s health and wider consumer safety.

The recall covers limited batches of several imported infant formulas, including NAN Comfort 1, NAN OPTIPRO 1, NAN SUPREME PRO 1, 2, 3, S-26 Ultima 1, 2, 3, and Alfamino, which are widely used by parents, with the Emirates Drug Establishment confirming that all other Nestlé nutritional products remain available and approved for consumption.

The Emirates Drug Establishment reported that testing identified Bacillus cereus in one ingredient used during manufacturing, noting that this bacterium can generate cereulide toxin, which has been linked to foodborne illness, and explaining that the recall decision followed risk assessment procedures designed to minimise any potential impact on vulnerable infant groups.

According to the Emirates Drug Establishment, there have been no confirmed cases of illness or adverse reactions associated with the affected batches so far, and health authorities continue to monitor reports from medical facilities and distributors, underlining that product quality and safety for infants remain a primary policy objective.

In cooperation with Nestlé, the Emirates Drug Establishment has ensured that impacted batches are quarantined at company and distributor warehouses, while teams work to remove any remaining units from circulation through approved recall protocols, covering both traditional retail outlets and online sales platforms across all emirates.

The Emirates Drug Establishment stated that these measures form part of broader efforts to strengthen national pharmaceutical security, including the reliable availability of safe medical products, and highlighted that the current recall is being carried out with the involvement of relevant UAE regulatory bodies to guarantee that all flagged batches are fully withdrawn.

{TABLE_1}

The Emirates Drug Establishment added that it operates a regulatory system based on proactive risk analysis and continuous oversight of domestic and international pharmaceutical supply chains, which supports a rapid response to any quality incident, helps maintain market stability, and provides reassurance to businesses and consumers about the safety of infant formula products.

With inputs from WAM